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Abstract
Background: Triggering receptor expressed on myeloid cells 2 (TREM2) and apolipoprotein E (APOE) are genetically
linked to Alzheimer’s disease. Here, we investigated whether human ApoE mediates signal transduction through
human and murine TREM2 and sought to identify a TREM2-binding domain in human ApoE.
Methods: To investigate cell signaling through TREM2, a cell line was used which expressed an NFAT-inducible
β-galactosidase reporter and human or murine TREM2, fused to CD8 transmembrane and CD3ζ intracellular
signaling domains. ELISA-based binding assays were used to determine binding affinities of human ApoE
isoforms to human TREM2 and to identify a TREM2-binding domain in ApoE.
Results: ApoE was found to be an agonist to human TREM2 with EC50 in the low nM range, and to murine
TREM2 with reduced potency. In the reporter cells, TREM2 expression was lower than in nontransgenic mouse
brain. Human ApoE isoforms ε2, ε3, and ε4 bound to human TREM2 with Kd in the low nM range. The binding
was displaced by an ApoE-mimetic peptide (amino acids 130–149).
Conclusions: An ApoE-mediated dose-dependent signal transduction through TREM2 in reporter cells was
demonstrated, and a TREM2-binding region in ApoE was identified. The relevance of an ApoE-TREM2 receptor
signaling pathway to Alzheimer’s disease is discussed.
Keywords: Alzheimer’s disease, Apolipoprotein E (ApoE), Triggering receptor expressed on myeloid cells 2 (TREM2),
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Background
Triggering receptor expressed on myeloid cells 2 (TREM2)
is part of the immunoglobulin-lectin-like receptor super-
family, and in the brain, TREM2 is expressed mainly in
microglial cells. TREM2 couples to DNAX-activating pro-
tein of 12 kDa (DAP12) and activates its downstream tar-
gets through the phosphorylation of the immunoreceptor
tyrosine-based activation motif (ITAM) of DAP12. TREM2
function has been related to phagocytosis, cell growth,
regulation of actin cytoskeleton, migration towards che-
mokines, and cytokine release (reviewed in [1, 2]). The in-
heritance of a mutant variant of the TREM2 gene, R47H,
confers a markedly increased risk for developing late-onset
[3, 4] and early-onset [5] Alzheimer’s disease (AD). TREM2
expression has been found in the close vicinity of amyloid
plaques in AD brain and transgenic mouse models, par-
ticularly in microglia and infiltrating macrophages sur-
rounding plaques [6, 7]. Moreover, loss-of-function
mutations in TREM2 are linked to an increased risk of de-
veloping Nasu-Hakola disease, frontotemporal dementia,
Parkinson’s disease, and sporadic amyotrophic lateral
sclerosis [8–13]. This suggests a significant role for
TREM2 in neurodegenerative diseases with phenotypes be-
ing dependent upon the location of the mutation and the
severity of protein dysfunction [14]. Since TREM2 variants
seem broadly involved in neurodegeneration, there is an
urgent need to further investigate the functions of TREM2
in the brain and to find ligands involved in TREM2-
mediated signaling and their role in AD pathogenesis.
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Another strong risk factor for developing late-onset
AD is the ε4 allele of the apolipoprotein E gene (APOE),
which is far more prevalent than the R47H-TREM2 risk
factor [3]. The three major isoforms of ApoE in human
are the ApoE ε2 (cys112, cys158), ApoE ε3 (cys112,
arg158), and ApoE ε4 (arg112, arg158). The most com-
mon isoform is ApoE ε3, while ApoE ε2 isoform is rare.
The APOE4 allele increases the risk of AD by three- to
fourfold [15, 16], while APOE2 is protective [17]. The dis-
ease risk is gene dose-dependent for both alleles [15–17].
In the brain, astrocytes are the main source of ApoE, and
ApoE is the major regulator of lipid metabolism, transport-
ing cholesterol and phospholipids between cells (reviewed
in [18]). ApoE is intimately associated with fibrils of
amyloid-β (Aβ) in amyloid deposits in AD brain and trans-
genic animal models of AD [16, 19, 20]. Early studies re-
ported both inhibition and augmentation of Aβ fibril
formation when mixing ApoE and Aβ in vitro [21–25].
Some studies reported that the ApoE ε4 isoform bound
faster to Aβ and increased aggregation more readily than
the ApoE ε2 or ε3 isoforms [23, 25–27]. The interpretation
of such studies in relation to the brain is complicated by
the complex nature of Aβ (mixture of different lengths
and aggregation states) and ApoE (isoform and lipidation
state), which is difficult to mimic in vitro. A link between
human ApoE and amyloid plaque accumulation in
amyloid-β precursor protein (AβPP) transgenic mouse
brain has been consistently found [28–30]. Since mice
have an ApoE isoform distinct from the human isoforms,
these studies have mostly been done on AβPP transgenic
mice crossed with Apoe knockout mice (Apoe−/−) instead
expressing human APOE. Such studies have shown that
murine ApoE augments Aβ deposition more than either
of the human ApoE isoforms and that the order of fibrillo-
genic effect on Aβ of the human ApoE isoforms is ApoE
ε4 > ApoE ε3 > ApoE ε2 [28, 31, 32]. These results are
consistent with the relative risk associated with the ApoE
variants for developing AD. The effect of ApoE on Aβ ag-
gregation also depends on the human ApoE concentration
[30], as also reported for murine ApoE in the first AβPP/
ApoE cross-breeding study [33].
All three main human ApoE isoforms were recently
found to bind to human TREM2 in vitro [34, 35]. In a
recent paper, these findings were partly opposed, as
binding could not be detected between human TREM2
and nonlipidated human ApoE using protein microarray,
while lipidated human ApoE bound TREM2 when bio-
layer interferometry was used [36]. The reported experi-
ments were all done in pure in vitro (cell-free) settings
[34–36]. It remains unclear whether ApoE binds to
TREM2 when it resides on cell surfaces, and whether
ApoE serves as a TREM2 agonist. Experimental proof of
such an interaction would effectively link the two major
genetic risk factors for AD in a signaling pathway.
In this study, we used a cell reporter assay to provide
the first evidence of human ApoE-mediated intracellular
signaling through human TREM2, which is of great
importance for understanding of the interaction be-
tween ApoE and TREM2 in the AD pathogenesis. Pos-
sible interactions between human ApoE and murine
TREM2 have never been examined despite multiple
studies using transgenic AβPP mice expressing human
ApoE instead of murine ApoE. We report that human
ApoE signals through murine TREM2, albeit with a re-
duced efficacy. The Kd has previously only been deter-
mined for the ApoE ε3 isoform using dot blotting [34],
a semi-quantitative method. We developed a sensitive
ELISA-based binding assay to determine the affinity of
human TREM2 binding to the three major human
ApoE isoforms and, importantly, identified a TREM2-




Transparent Maxisorp 96-well plates (#442404), Roswell
Park Memorial Institute 1640 medium (RPMI; #61870-
044), Zeocin (#R250-01), ionomycin (#I-24222), 2-
mercaptoethanol (#31350-010), ethylenediaminetetraace-
tic acid (EDTA; #15575-020), trypan blue (#T10282), as
well as secondary horseradish peroxidase (HRP)-conju-
gated rabbit anti-goat (#31402) and goat anti-mouse
(#31430) antibodies were from Thermo Fischer Scientific
(Waltham, MA, USA). Phorbol myristate acetate (PMA;
#P1585), chlorophenol-red β-D-galactopyranoside (CPRG;
#59767), magnesium chloride hexahydrate (#M9272),
potassium chloride (#P5405), sodium phosphate dibasic
dehydrate (#30412), sodium chloride (#71376), phosphate-
buffered saline (PBS, pH 7.4; #P4417), sodium dodecyl sul-
fate (SDS; #L4390), Roche complete protease inhibitors
(#04-693-116-001), fetal bovine serum (FBS; #F7524), and
bovine serum albumin (BSA; #A7030) were from Sigma-
Aldrich (St. Louis, MO, USA). Monoclonal antibodies
against β-actin (clone AC-15) and FLAG-peptide sequence
DYKDDDDK (M2; #F1804) were also from Sigma-
Aldrich. Molecular biology grade 2-mercaptoethanol
(#A1108) was from AppliChem (Darmstadt, Germany).
Electran 1,4-dithiothreithol (Cleland’s reagent, DTT;
#443853B) and KPL LumiGLO kit (#54-71-00) were
from VWR (Radnor, PA, USA). 7.5 and 12% TGX poly-
acrylamide gels (Mini-protean; #4561026 and #4561043,
respectively) were from Bio-Rad (Hercules, CA, USA).
Saponin (#558255) and polyclonal goat anti-ApoE anti-
body (#178479) were from Merck Millipore (Darmstadt,
Germany). Polyclonal goat anti-TREM2 antibody
(#ab95470), preadsorbed unconjugated polyclonal rabbit
anti-rat antibody (#ab102248) and secondary HRP-
conjugated donkey anti-goat antibody (#ab7125) were
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from Abcam (Cambridge, UK). Recombinant human
ApoE ε2, ApoE ε3, and ApoE ε4 (#4760, #4696, and
#4699, respectively) were bought from BioVision (Milpitas,
CA, USA). Recombinant human TREM2 (#11084-H08H)
and mouse TREM2 (#50149-M08H) were bought from
Sino Biological Inc. (Beijing, China). An ApoE-mimetic
peptide corresponding to amino acids 130–149 (acetyl-
TEELRVRLASHLRKLRKRLL-amide) and a scrambled
peptide serving as negative control (acetyl-LREKKLRV-
SALRTHRLELRL-amide) were from GenScript (Piscataway,
NJ, USA). K-blue aqueous substrate (TMB; #331177) was
bought from ANL-Produkter (Älvsjö, Sweden). Monoclonal
rat antibodies were made towards TREM2 (clone 150; [37])
and T cell immunoglobulin domain and mucin domain 2
(TIM2) (clone N3-4; [38]).
Reporter cell lines
To investigate stimulation of TREM2 by ApoE, we used
a reporter cell line based on T lymphocytes in which the
α- and β-beta chains of the endogenous T cell receptor
had been knocked out, and the cells expressed lacZ
under a nuclear factor of activated T cells (NFAT) pro-
motor in an overexpression system [39, 40]. The cells
were used to generate the reporter cells that also express
human or murine TREM2. Here, TREM2 was linked in
a single transmembrane fusion construct to a chimeric
antigen receptor with the leader sequence and trans-
membrane CD8 domain fused with the intracellular
CD3ζ. When an agonist binds to TREM2, the ITAMs of
CD3ζ are phosphorylated, starting an intracellular signal-
ing cascade through zeta-chain-associated protein kinase
70 (ZAP-70) thereby increasing the intracellular Ca2+ con-
centration. This resembles the physiological signaling of
TREM2 through DAP12, in which ITAM-phosphorylation
also recruits ZAP-70 [41]. The NFAT promotor is acti-
vated in response to the increased intracellular Ca2+ con-
centration [39, 40] such that β-galactosidase is expressed.
Since β-galactosidase is expressed as a result of TREM2
signal transduction and NFAT promoter activity, we can
determine the level of TREM2-stimulation by measuring
the product generated by a colorimetric β-galactosidase
substrate, CPRG (Fig. 1).
All cells were grown in RPMI supplemented with 1%
penicillin + streptomycin, 5% FBS, 50 μM EDTA, and
50 μM 2-mercaptoethanol (termed cRPMI) in a cell in-






Fig. 1 Signal transduction mechanism and detection principle of the BWZ reporter assays. In the BWZ cells, TREM2 (shown in blue) is expressed in
a single chimeric protein containing CD8 transmembrane domain (shown in green) and a CD3ζ domain (shown in purple and pink), with an
extracellular FLAG-tag (shown in brown). When a TREM2 ligand, here ApoE, binds to TREM2 (a), the CD3ζ ITAM motifs (shown in purple) are phos-
phorylated (b), which leads to an intracellular signaling cascade resulting in an increased intracellular Ca2+ concentration. This induces the NFAT
promoter, so that β-galactosidase is expressed from the lacZ gene (c). β-galactosidase is released from the cells using a lysis buffer containing sap-
onin (d). The yellow β-galactosidase substrate, CPRG, is also present in the lysis buffer, and when cleaved by β-galactosidase, it forms a red product
which is measured by absorbance (e)
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based on an immortalized T lymphocyte cell line [39, 40]
and constitutively express 3xNFAT/LacZ. Naïve BWZ.36
cells were transfected by electroporation with human
TREM2-CD8-CD3ζ pcDNA4 (BWZ-hTREM2), murine
Trem2-CD8-CD3ζ pcDNA4 (BWZ-mTREM2), or TIM2-
CD8-CD3ζ pcDNA4 (BWZ-TIM2), all with a FLAG-tag
sequence incorporated as described elsewhere [37, 38].
TIM2 shows partial homology to the Ig domain of
TREM2 [38]. Successfully transfected cells were se-
lected with Zeocin (0.75 mg/mL).
Reporter assays
For testing stimulation of human and murine TREM2,
we used a modified version of a reporter cell assay ori-
ginally described by Sanderson and Shastri [40]. Cells
used in reporter assays were counted using 0.2% trypan
blue and Invitrogen Countess automated cell counter
(Thermo Fischer Scientific) and used only if the viability
was above 90%.
Transparent Maxisorp 96-well plates were used for the
reporter assays. All coatings were done for 1 h at 37 °C
in sterile, special PBS with reduced ionic strength (S-
PBS; pH 7.4): 10 mM Na2HPO4, 2 mM KH2PO4,
13.7 mM NaCl, and 0.27 mM KCl. The wells of the plate
were coated either with 2.5 μg/mL preadsorbed, uncon-
jugated polyclonal rabbit anti-rat antibody, recombinant
human ApoE ε2, ApoE ε3, or ApoE ε4 (3–300 nM di-
luted in S-PBS), or S-PBS alone. Between coating and
adding BWZ cells to the plate (2.4 × 105 cells in cRPMI
per well), the wells were carefully washed once with ster-
ile S-PBS. All BWZ cells were mixed with different stim-
uli together with 3.3 nM PMA as a costimulating agent
and incubated for 4 h in a cell chamber with 37 °C and
5% CO2. The stimuli used were 3.7 or 5.2 nM monoclo-
nal rat anti-TIM2 antibody [38] or 3.3 nM monoclonal
rat anti-TREM2 antibody (“ab150”). The Ab150 anti-
body, also called clone 150.1, was produced at the same
time as clone 78.18 referenced in [42], although ab150
(clone 150.1) is subclass IgG2a, while 78.18 is IgG1 [43].
Clone 150.1 detects both human and murine TREM2 in
flow cytometry (unpublished data) and stimulates both
human and murine TREM2 in our reporter assays. Thus,
ab150 was used as a positive control for TREM2 recep-
tor signaling, while the anti-TIM2 antibody was used as
a positive control for TIM2 receptor signaling. After in-
cubation with the stimuli, the cells were carefully
washed once with Hi-S-PBS (high phosphate content
and low saline content: 60.7 mM Na2HPO4, 13.2 mM
KH2PO4, 0.27 mM KCl, and 13.7 mM NaCl). Finally,
freshly prepared lysis buffer with CPRG substrate was
added to the wells: 3 mM CPRG in Hi-S-PBS with
5 mM DTT, 20 mM MgCl2, and 0.2% (w/v) saponin.
Volumes of added cells, coating solutions, washing solu-
tions, and lysis buffers were all 200 μL/well.
The absorbance was monitored from once the enzym-
atic reaction had started and onwards for 4 h at 570 nm
(specific signal) and 700 nm (background) with a Spec-
traMax 190 plate reader (Molecular Devices). The plate
was tightly sealed and placed gently shaking at 37 °C be-
tween measurements. The absorbance at λ700 nm back-
ground was subtracted from the specific signal at λ570 nm
when processing the data. All results presented in this
paper are from 4 h after adding the CPRG-containing
lysis buffer to the stimulated cells. All measurements
were made in triplicate.
Protein extraction and western blot
BWZ reporter cells, 14-month-old nontransgenic C57BL/
6 J mouse brain, and 6-month-old Trem2-knockout mouse
brain were extracted with a Potter-Elvehjem homogenizer
(#432-5015; VWR) by manual homogenization on ice with
two times of ten strokes in ice-cooled 1% (w/v) SDS in
20 mM Tris-HCl (pH 7.5), 137 mM NaCl, and 4 mM
EDTA with complete protease inhibitors. The resulting
homogenate was centrifuged at 100,000g for 1 h at +4 °C
in a Beckman Optima LE-80 K ultracentrifuge with a Sw-
60Ti rotor. After centrifugation, the supernatant was
stored at −80 °C until use. SDS-protein extracts (30–50 μg
total protein) were mixed with Laemmli buffer containing
β-mercaptoethanol (1% v/v) and bromophenol blue
(62.5 mg/L), heat-denatured at 75 °C for 5 min, and sepa-
rated by electrophoresis at 160 V. Proteins were trans-
ferred to nitrocellulose membranes with Trans-Blot semi-
dry transfer system at 20 V for 30 min. The filters were
blocked for 1 h at 37 °C with 5% (w/v) non-dry milk pow-
der in a Tris-buffered saline (TBS) buffer containing 0.1%
Tween-20 before being incubated with primary antibodies
recognizing either murine TREM2 (0.1 μg/mL) or FLAG-
tag M2-epitope (1 μg/mL) overnight at 4 °C. The mem-
branes were then incubated 30 min at room temperature
(RT) with secondary rabbit anti-goat (0.08 μg/mL) or goat
anti-mouse (0.08 μg/mL) HRP-conjugated antibodies. The
immunoreactive bands were visualized with enhanced
chemiluminescence substrate using a LumiGLO kit. After
stripping of the membranes, they were incubated for
30 min at RT with an antibody against β-actin (1:25000
dilution), followed by 30 min incubation at RT with sec-
ondary goat anti-mouse (0.08 μg/mL) HRP-conjugated
antibody and development with LumiGLO. Optical dens-
ities of the immunoreactive bands were quantified with
Image Pro Plus (Media Cybernetics, Rockville, MD, USA).
Western blots were performed two to three times, and
representative images are shown.
In vitro binding assay
Transparent Maxisorp 96-well plates were coated with
recombinant human TREM2 (40 nM) on a shaking plat-
form for 1 h at 37 °C in sterile PBS (pH 7.4). The plates
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were blocked with 1% (w/v) BSA (fatty acid free) in PBS
for 1 h at 37 °C before being incubated with recombin-
ant human ApoE (ε2, ε3, or ε4) at various concentrations
for 1 h at RT. The plates were then incubated for 1 h at
RT with 12 ng/mL polyclonal goat anti-ApoE antibody
followed by 1 h at RT with 20 ng/mL donkey anti-goat
HRP-conjugated antibody. Finally, the assay was devel-
oped with K-blue aqueous substrate (TMB) for 15 min
at RT, and the reaction was stopped with 1 M H2SO4.
Absorbance was measured at 450 nm with a SpectraMax
190 plate reader (Molecular Devices). The plates were
washed between each step with PBS with 0.05% (w/v)
Tween-20.
In vitro competition assay
Transparent Maxisorp 96-well plates were coated with
recombinant human TREM2 (40 nM in sterile PBS)
shaking for 90 min at 37 °C. The plates were blocked
1 h on a shaking platform at 37 °C with 1% (w/v) BSA
(fatty acid-free) in PBS before being incubated 1 h at RT
on a shaking platform with 6 nM recombinant human
ApoE (ε2, ε3, or ε4) and various concentrations of
ApoE-mim149 or scrambled peptide (0–6 μM). For de-
tection of ApoE bound to TREM2, a polyclonal goat
anti-ApoE antibody (18 ng/mL) was used that only de-
tects full-length ApoE, but not ApoE-mim149 or scram-
bled peptide (Additional file 1: Figure S1) and incubated
1 h on shaker at RT followed by incubation with a don-
key anti-goat HRP-conjugated antibody (33 ng/mL) for
30 min on shaker at RT. The assay was developed with
K-blue aqueous substrate (TMB) for 30 min at RT, and
the reaction was stopped with 1 M H2SO4. Absorbance
was measured at 450 nm with a SpectraMax 190 plate
reader (Molecular Devices).
Statistics
All experiments were performed three times with tripli-
cates unless otherwise stated. GraphPad Prism vs. 5.04
(San Diego, CA, USA) was used for graphs and statistical
analyses. For analyzing dose-response and binding
curves, data from at least three independent experiments
were pooled and normalized. Normalization of all data
was done using the formula Y = ((X−L)/(K−L))* 100% (in
which Y represents the normalized data point, X repre-
sents the raw data point, L represents the mean of the
0% data point, which was the lowest concentration of
ApoE used, and K represents the mean of the 100% data
point with highest signals). Kd, EC50, and Hill coefficients
were calculated using the “log (agonist) vs. normalized re-
sponse (variable)” function and were compared using one-
way ANOVA with Bonferroni post-test. For the competi-
tion assay between full-length ApoE and ApoE-mim149,
the Ki values were found by using the “one site-fit Ki”
function with 6 nM set as HotNM for all isoforms, and
HotKdNM set as the respective ApoE isoform Kd values
calculated in the binding assay. For comparing effects of
adding ApoE-mim149 to full-length ApoE, data points
were compared individually using an unpaired t test for
each ApoE-mim149 concentration. All reported p values
are two-tailed.
Results
ApoE ε3 stimulates human TREM2-, but not TIM2-
transfected reporter cells
We wanted to investigate whether stimulation with the
most common human ApoE isoform, ApoE ε3, would
induce human TREM2 signaling. For this, reporter cells
were generated with TREM2-CD8-CD3ζ and NFAT/lacZ
constructs. When an agonist binds to TREM2 in these
cells, an intracellular signaling cascade is initiated
through the ITAM motif of CD3ζ. As a result of extra-
cellular TREM2-stimulation, β-galactosidase expression
is induced by the NFAT promoter (Fig. 1). A colorimet-
ric CPRG-assay was used to detect TREM2 signal trans-
duction in the reporter cells. We compared stimulation
of BWZ-hTREM2 cells to that of TIM2-transfected cells.
TIM2 shows partial homology to the Ig domain of
TREM2; the production of the cells is described in [38].
All cells were stimulated with PMA, and cells that were
PMA-stimulated, but not incubated with any other stim-
uli, were used as negative controls. An anti-TREM2 anti-
body was used as positive control for stimulation of
BWZ-hTREM2 receptor signaling. An anti-TIM2 anti-
body was used as positive control for stimulation of
BWZ-TIM2 receptor signaling. We found that ApoE ε3
was an agonist for human TREM2 (Fig. 2) and demon-
strated a dose-dependent signaling effect in BWZ-
hTREM2 cells that markedly differed from BWZ-TIM2
cells. As might be noted in Fig. 2, the cells displayed a
weak dose-dependent ApoE-mediated background (p <
0.05) that was independent of transfection with TREM2.
This background was likely caused by ApoE acting on
other receptors on the T lymphocytes, such as the low-
density lipoprotein receptor (LDLR) [44–46], possibly
resulting in a minor increase in the intracellular Ca2+
concentration. However, the potential background effects
of stimulation of other receptors are small in comparison
to stimulation of TREM2.
ApoE ε2, ApoE ε3, and ApoE ε4 are all agonists for both
human and murine TREM2
Next, we examined if the other two human isoforms of
ApoE, ε2 and ε4, were likewise agonists for human
TREM2. For ApoE stimulation of human TREM2, EC50
was 27, 33, and 34 nM for ApoE ε2, ApoE ε3, and ApoE
ε4, respectively (Fig. 3a; ε2 −logEC50 = 7.57 ± 0.06 M, ε3
−logEC50 = 7.48 ± 0.04 M, ε4 −logEC50 = 7.47 ± 0.05 M).
There was no statistically significant difference in EC50
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Fig. 2 Dose-dependent ApoE ε3-induced signal transduction in BWZ reporter cells expressing human TREM2. A dose-dependent stimulation of
signal transduction in BWZ-hTREM2 cells was observed when cells were incubated in wells coated with an increasing concentration of recombinant
ApoE ε3. Stimulation of BWZ-hTREM2 cells was compared to stimulation of BWZ cells instead transfected with TIM2 (BWZ-TIM2). All cells were
stimulated with PMA (3.3 nM). As a positive control of BWZ-hTREM2 stimulation, cells were incubated with a rat anti-TREM2 antibody (“α-T2”)
in solution in wells coated with an anti-rat antibody. As a positive control for TIM2 stimulation, a rat anti-TIM2 antibody (“α-TIM2”) was used in
conjunction with coating wells with anti-rat antibody similarly as for the BWZ-hTREM2 cells. Negative controls for both cell lines included cells
stimulated only with PMA (“PMA only”), or cells growing in anti-rat coated wells (“coating only”). The columns depict mean ± SEM, and reflect
data from three individual experiments with triplicates
A B
Fig. 3 The three human ApoE isoforms serve as agonists for human and murine TREM2. Human ApoE ε2 (inverted green triangle), ε3 (light blue diamond),
and ε4 (red triangle) all stimulated human (a) and murine (b) TREM2 receptor signal transduction in a dose-dependent manner. EC50 for human
ApoE was 27, 33, and 34 nM for ApoE ε2, ε3, and ε4, respectively. EC50 for murine TREM2 was 40, 54, and 39 for ApoE ε2, ε3, and ε4, respectively.
The points depict mean ± SEM of all responses measured in triplicates from five (human TREM2) and three (murine TREM2) independent experiments.
Data from each ApoE isoform was normalized individually as described in the “Methods” section. The scale of the x-axis is logarithmic and shows
concentration of human ApoE in M
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between the isoforms. We also performed the same exper-
iments with murine TREM2 and determined EC50 for
both human and murine TREM2. For murine TREM2, the
EC50 was 40, 54, and 39 nM for ApoE ε2, ApoE ε3, and
ApoE ε4, respectively (Fig. 3b; ε2 −logEC50 = 7.40 ±
0.02 M, ε3 −logEC50 = 7.27 ± 0.03 M, ε4 −logEC50 = 7.41 ±
0.04 M). The EC50 was significantly higher for ApoE ε3
than for ApoE ε2 and ε4 (p < 0.001 for both). There was
no significant difference between ApoE ε2 and ApoE ε4
(p > 0.05). The dose-response curve for ApoE stimulation
of human TREM2 showed Hill coefficients between 1 and
2 (ε2 1.0 ± 0.1, ε3 1.4 ± 0.2, ε4 1.7 ± 0.2 (Fig. 3a), with
statistically significant difference between ApoE ε2 and ε4
(p < 0.001). The Hill coefficients for murine TREM2 were
also between 1 and 2 (2.0 ± 0.1, 1.6 ± 0.1, and 1.6 ± 0.2 for
ApoE ε2, ε3, and ε4, respectively) (Fig. 3b). There was no
statistically significant difference between Hill coefficients
of isoforms for murine TREM2 (p > 0.05).
In order to compare the expression levels of TREM2
in the BWZ-mTREM2 and BWZ-hTREM2 cells, western
blots were semi-quantified with densitometry. We found
that the expression level was 7.5% (±0.2%) higher in
BWZ-mTREM2 than in BWZ-hTREM2 cells (Fig. 4a),
although the difference was not statistically significant
(p > 0.05; n = 2 for each cell line). We furthermore found
that TREM2 protein expression in an SDS extract of the
BWZ cells was lower than that of a brain SDS extract
from a 14-month-old nontransgenic C57BL/6J mouse
(≈1 ng TREM2/μg total protein; Fig. 4b, c). Only a faint
co-migrating band was detected in the SDS-extract of
Trem2-knockout mouse brain (Fig. 4b). The limitations
of the western blot experiments are mentioned in the
“Discussion” section.
ApoE ε2, ApoE ε3, and ApoE ε4 bind to recombinant
human TREM2 with high affinity
In order to determine affinity of the binding between
ApoE and TREM2, we established an in vitro ELISA-
based binding assay. Nonlipidated human ApoE bound
to recombinant human TREM2 with high affinity.
There were only small differences between isoforms
with Kd of 13, 16, and 9.5 nM for ApoE ε2, ApoE ε3,
and ApoE ε4, respectively (Fig. 5; ε2 −logKd = 7.87 ±
0.02 M, ε3 −logKd = 7.78 ± 0.03 M, ε4 −logKd = 8.02 ±
0.03 M). The Kd of ApoE ε4 was lower than the Kd of
ApoE ε3 (p < 0.001) and ApoE ε2 (p < 0.001). The Hill
coefficients were similar for ApoE ε2 (1.4 ± 0.1), ApoE
ε3 (1.3 ± 0.1), and ApoE ε4 (1.4 ± 0.1) (p > 0.05).
Amino acids 130–149 in human ApoE contain a binding
domain for human TREM2
Previously, it has been found that the human ApoE frag-
ment “ApoE-mim149” (amino acids 130-149 of ApoE)
modulates microglial immune response [47]. To investigate
whether this region contains a binding domain for human
TREM2, we let ApoE-mim149 peptide and ApoE compete
for binding to human TREM2. Adding human ApoE and
ApoE-mim149 simultaneously to recombinant, human
TREM2 resulted in reduced binding of ApoE to TREM2
with an increasing concentration of ApoE-mim149 in the
mixture (p < 0.001 for all three ApoE isoforms at both
6 μM and 0.6 μM concentration of ApoE-mim149). This
effect was not seen when instead an increasing concentra-
tion of a scrambled peptide (altered sequence of amino
acids 130–149 of ApoE) was supplemented, indicating that
a TREM2-binding region is present in amino acids 130–
149 of human ApoE (Fig. 6). The Ki values for the three
A B C
Fig. 4 Rougly similar level of TREM2 in BWZ-mTREM2 and hTREM2 cells and lower than in mouse brain. a In both the BWZ-mTREM2 and
BWZ-hTREM2 reporter cells, the TREM2 constructs harbor a FLAG-tag. A western blot with an antibody detecting the FLAG-tag expression in the
reporter cells indirectly showed that the TREM2 level was slightly higher in the BWZ-mTREM2 than in the BWZ-hTREM2 cells, although this was
not statistically significant (n = 2 for both cell lines). Protein loading was 30 μg (lanes 1–2) and 50 μg (lanes 3–4). b Western blot detection of
murine TREM2 in BWZ-mTREM2 cells (“BWZ-mT2”) compared to a nontransgenic mouse brain (“ntg ms”). Protein loading was 30 μg (lanes 1–2)
and 50 μg (lanes 3–4). TREM2 in the nontransgenic mouse brain was also compared to Trem2 knockout mouse brain (“KO ms”). Protein loading
was 40 μg in both lanes. c The level of TREM2 protein in the nontransgenic mouse brain was estimated to approximately 1 ng/μg protein by
using recombinant mouse TREM2 (“recT2”) as a standard. Mouse brain extract (30 μg total protein) was loaded in lane 1, while 40 and 80 ng
pure, recombinant TREM2 was loaded in lanes 2 and 3, respectively
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ApoE ε2, ε3, and ε4 with ApoE-mim149 present were 827,
475, and 1537 nM, respectively (ε2 −logKi = 6.08 ± 0.1; ε3
−logKi = 6.32 ± 0.1; ε4 −logKi = 5.81 ± 0.1). The Ki for ApoE
ε4 was significantly higher than for ApoE ε3 (p < 0.001).
Discussion
APOE and TREM2 are the two most predominant gen-
etic risk factors in AD. Previous papers have reported
binding between human ApoE and human TREM2 only
in pure in vitro settings [34–36], but did not contain in-
vestigations on whether ApoE was an agonist mediating
intracellular signaling through TREM2, or alternatively an
antagonist inhibiting other stimuli. In this study, using cell
reporter assays, we provide the first evidence that ApoE
and TREM2 interact in a signaling pathway. With a sensi-
tive ELISA-based binding assay, we have determined bind-
ing affinities of human ApoE ε2, ε3, and ε4 to human
TREM2 to be in the low nM range. Importantly, we report
the first evidence that a TREM2-binding domain is found
in amino acids 130–149 of human ApoE, which is the
conserved receptor-binding domain in the main ApoE iso-
forms, ε2, ε3, and ε4, as reviewed in [48].
Fig. 5 High-affinity binding of recombinant human ApoE ε2, ε3, and ε4 to recombinant human TREM2. In an ELISA-based binding assay with
recombinant human TREM2 and recombinant human ApoE, ApoE ε2 (inverted green triangle), ApoE ε3 (light blue diamond), and ApoE ε4 (red
triangle) isoforms bound to human TREM2 in vitro with Kd of 13, 16, and 9.5 nM, respectively. The points depict mean ± SEM of all responses
that were measured in triplicates from three independent experiments. Data from each ApoE isoform was normalized individually as described
in the “Methods” section. The x-axis shows the ApoE concentrations (in M) on a logarithmic scale
Fig. 6 An ApoE-mimetic peptide (amino acids 130–149) reduced binding of human ApoE to human TREM2. An ApoE-mimetic (amino acids
130–149) or a scrambled peptide was allowed to compete with ApoE for binding to immobilized recombinant human TREM2 in the ELISA-
based assay. This led to reduced binding of ApoE, isoforms ε2 (inverted green triangle), ε3 (light blue diamond), and ε4 (red triangle), to human
TREM2 with Ki of 827, 475, and 1537 nM for ApoE ε2, ε3, and ε4, respectively. The points depict mean ± SEM of binding measured in duplicates
from four independent experiments. The data was normalized to maximum (100%), which is binding of ApoE in the absence of a competing
peptide, and minimum (0%), which is signal in the absence of ApoE as well as a TREM2-coat. The x-axis shows ApoE-mim149 or scrambled
peptide concentration (in M) on a logarithmic scale
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By using an ELISA-based binding assay, we found a
statistically significant lower Kd for ApoE ε4 (9.5 nM)
than for ApoE ε2 and ApoE ε3 (13 and 16 nM, respect-
ively), while the EC50 for human TREM2-signaling was
similar among the ApoE isoforms (27, 33, and 34 nM for
ApoE ε2, ε3, and ε4, respectively). Since we found a
TREM2-binding domain in a conserved region of ApoE
(amino acids 130–149), it is reasonable to expect equal
binding affinity between the recombinant human ApoE
isoforms, as was also previously reported [34, 35]. The
biological relevance of potential isoform differences in
TREM2 stimulation, if any, needs to be further investi-
gated by in vivo modeling. The EC50 data found are in
the physiologically relevant range, since the ApoE concen-
tration is between 60–300 nM in the human cerebrospinal
fluid (CSF) and 880–2700 nM in the plasma [49–53]. In
the brain, it can generally be expected that the concentra-
tion of a given protein depends on location. The availabil-
ity of a ligand to a receptor also depends on its binding to
other proteins. Accordingly, ApoE is likely to be present
in higher local concentrations in amyloid plaques and
close to cell surfaces of astrocytes, and the CSF concentra-
tion gives only a rough estimate of the ApoE concentra-
tion in the brain. With western blots, we did not find
evidence that TREM2 was overexpressed in the BWZ re-
porter cells as compared to the brain from a nontrans-
genic 14-month-old mouse. Using Trem2 knockout brain
tissue, we showed that the immunoreactive band in tissue
extract of the nontransgenic mouse brain is largely derived
from murine TREM2. The major limitation with the west-
ern blot experiments is that the binding of the TREM2
antibody might depend on TREM2 glycosylation, which
presumably differs between native TREM2 in mouse
brain and TREM2 in transfected BWZ cells, and surely
with nonglycosylated recombinant TREM2. The
TREM2 antibody used was chosen since it was raised
against a domain (amino acids 154–165 of mouse
TREM2), which is distinct from the location of the N-
glycosylation, which occurs at amino acids 20 and 80
[54]. Yet, it still cannot be excluded that differential
glycosylation still plays a role. A 40–45-kDa size of the
TREM2 immunoreactive band from brain extract is
quite consistent with previous observations [55]. Glyco-
sylation structure and complexity affects migration of
proteins on a polyacrylamide gel. The vector should en-
code a TREM2 fusion protein of ≈36 kDa, but since it
is expressed in a cell line, the protein glycosylation is
likely to be less complex than that of the native TREM2
protein in mouse brain.
By stimulating BWZ-hTREM2 reporter cells with ApoE,
we found a significantly higher Hill coefficient for ApoE
ε4 (1.7) than for ApoE ε2 (1.0). When using a sensitive
ELISA-based binding assay, we found similar Hill coeffi-
cients between the ApoE isoforms when bound to
recombinant, human TREM2. The relevance of binding
differences needs to be further explored with other experi-
mental techniques such as structural modeling of human
TREM2 bound by ApoE isoforms.
It might be tempting to conclude that the risk of AD
does not depend on ApoE/TREM2 signaling since we
did not find evidence of ApoE isoform-dependent differ-
ences in binding to or signaling through TREM2. How-
ever, other factors could play a role in vivo: (1) It has been
shown that the ApoE concentration in CSF depends on
APOE genotype [51], making it plausible that individuals
homozygous for APOE4 exhibit diminished stimulation of
TREM2 as a result of lower ApoE concentration; (2) the
outcome of the ApoE-mediated intracellular signaling
through TREM2 could vary depending on ApoE isoforms
due to cofactors with different binding affinities exerting
effects on structure and stability, or perhaps even down-
stream targets of the intracellular signaling through
TREM2. Thus, it is still possible that the ApoE/TREM2
interaction contributes to the ApoE isoform-dependent
AD risk.
Ligand-induced receptor signaling also depends on in-
teractions with other constituents in the membrane and
on anchoring proteins. Heparan sulfate proteoglycan
(HSPG) is a possible cofactor that could be involved in
the ApoE stimulation of TREM2. HSPGs are ubiqui-
tously present on cell surfaces and in extracellular matri-
ces, and the heparan sulfate (HS) side chains can bind
ApoE [56–58]. Interestingly, both the receptor-binding
region and the lipid-binding region of ApoE are involved in
binding to HS [57–63]. HSPGs are known to regulate the
interaction between ligands and their receptors [64–67]. In
this sense, ApoE ε2 binds more readily to HS than ApoE ε3
[56, 68], thus perhaps differentiating the ApoE ε2-mediated
activation of TREM2 from the ApoE ε3-mediated acti-
vation. Interestingly, HS and ApoE are both present in
amyloid plaques in AD and animal models [69–73].
Another possible cofactor for the ApoE/TREM2 sig-
naling is Aβ. While Aβ has been reported to bind both
the lipid-binding region (amino acids 244–272) and the
receptor-binding region (within amino acids 130–149) of
ApoE [26, 74], it is interesting to note that Aβ binding
to the lipid-binding region of ApoE would allow for the
possibility of stimulation of TREM2 by the Aβ/ApoE
complexes found in or around amyloid plaques.
A link between ApoE and Aβ has been found consist-
ently, as APOE dose-dependently enhances the risk of
developing late-onset AD and also increases amyloid
burden among those carrying ε4 alleles [15, 75]. Like-
wise, in APPV717F transgenic mice, the ApoE ε4 isoform
was found to increase Aβ deposition [28] and decrease
Aβ clearance [32], although the specific clearance path-
way involved is still incompletely understood. In
C57BL/6 mice, ApoE (lipid-poor or lipid-rich) and Aβ
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(monomeric Aβ40 or Aβ42) were injected intracerebrally
either alone or in ApoE-Aβ complexes. The authors
found decreased Aβ clearance associated with the ApoE
ε4 isoform [76]. Since ApoE is associated with Aβ in
amyloid plaques and TREM2 is found in microglia or
macrophages adjacent to the plaques [6, 7], it is intri-
guing to think that there might be a connection between
Aβ/ApoE complexes and TREM2 on surrounding
microglia/macrophages.
While reduced ApoE gene dosage consistently amelio-
rates AD phenotypes [30, 33], there has been conflicting
reports on gene dosage effects of TREM2 in AβPP trans-
genic mice [7, 77, 78]. Reduced TREM2 gene dosage was
found to enhance amyloid pathology in one of the studies
[78], while it decreased amyloid pathology in another
study [7]. Importantly, the latter group recently showed
that TREM2 deficiency in APP/PS1 mice lead to reduced
amyloid burden at an early disease stage, while it en-
hanced amyloid burden at a late disease stage [79]. When
AD pathogenesis is investigated in transgenic mouse
models, human ApoE isoforms are often expressed, either
by using a heterologous promoter [80] or by gene replace-
ment in animals devoid of murine ApoE [81]. Knowing
that the TREM2/ApoE interaction is presumably relevant
to AD pathogenesis and perhaps also to other neurode-
generative diseases, we found it essential to determine the
extent to which human ApoE stimulated murine TREM2
signaling. Such information is needed to better interpret
studies with mouse models of disease. We found that all
three human ApoE isoforms were agonists to murine
TREM2 albeit with slightly reduced efficacy compared to
human TREM2. Therefore, double transgenic ApoE/AβPP
animal models might inadequately reflect the interactions
between ApoE and TREM2 in the AD brain; microglial
activation triggered by ApoE stimulation of murine
TREM2 might be more modest in transgenic mice than
when TREM2 in AD brain is exposed to the same stimuli.
Thus, it could be worth the effort to create human
TREM2 knock-in models, or at least to insert exons en-
coding the extracellular domains of human TREM2 into
the murine genome.
The ApoE/TREM2 interaction as observed by us might
be involved in a clearance pathway, which is consistent
with experiments with transgenic mice convincingly
linking ApoE to Aβ clearance [28, 32]. ApoE could poten-
tially also regulate responses of macrophages or micro-
glia to specific stimuli of neuroinflammation and lipid
metabolism and activate specific cellular functions such
as phagocytosis. Microglia do not express TREM2
constitutively on the cell surface [82], thus complicating
investigations of ligand-receptor interactions with
primary cells in vitro. The reporter cells used here serve
as an efficient and sensitive tool delivering reliable
quantitative data on ligand-receptor interactions and
signaling. However, there might be differences in the
cell-surface expression of proteins or glycoproteins
(possibly functioning as cofactors to TREM2) as well as
intracellular signaling cascade between reporter cells
and microglia/macrophages.
In the plasma, the ApoE isoforms differentially bind to
lipids, with ApoE ε2 and ε3 preferring high-density lipo-
protein (HDL) lipids and ApoE ε4 preferring low-density
lipoproteins (LDL) and very low-density lipoprotein
(VLDL) lipids [48, 83–86]. However, the intact BBB of
the adult brain confers a barrier through which neither
lipoproteins nor lipids can pass, thus creating a restrict-
ive environment that is distinct from the plasma. In this
manner, LDL and VLDL are not present in the CNS,
and the astroglial-derived HDL particles are structurally
different from those found in the plasma (see [18] for a
review on CNS lipoproteins). However, the lipoprotein-
affecting enzymes, transporters, and receptors present in
the periphery are also found in the CNS [18], and differ-
ent binding affinities have been reported for the ApoE
isoforms to their receptors, which can also be affected
by ApoE lipidation state for some receptors [76, 87, 88].
Using reporter cells, it was recently found that various
anionic lipids found in AD amyloid plaques were ago-
nists for TREM2 [78]. Since ApoE is a lipid carrier, the
ApoE/TREM2 interaction is likely to be involved in lipid
sensing by TREM2 [78, 89], although we hereby demon-
strate that the nonlipidated ApoE protein is sufficient
for a high-affinity interaction. Initial studies of TREM2
ligand binding suggested that TREM2 could function as
a pattern recognition receptor distinguishing negatively
charged motifs [37]. In addition to ApoE binding, other
apolipoproteins, ApoA1, ApoA2, ApoB, and ApoJ, also
bind to TREM2 [34–36]. Binding of lipidated as well as
nonlipidated human ApoE to human TREM2 has been
demonstrated [34–36]. In our cell reporter assays, ApoE
is bound to a Maxisorp plate, and it is unlikely that
lipids from cells or FBS will lipidate ApoE under these
circumstances. Also arguing against the necessity of
ApoE being lipidated in order to bind TREM2 is our
demonstration of high affinity binding between recom-
binant ApoE and recombinant TREM2 in a cell-free and
lipid-free ELISA binding assay. Moreover, the dose-
response curves for in vitro binding data and reporter
cell signaling data were quite similar, which further ar-
gues against lipidation of ApoE being necessary for
TREM2 signaling. Finally, the ApoE fragment, ApoE-
mim149, binds to TREM2. This peptide is derived from
the receptor-binding domain of ApoE, which is distinct
from the lipid-binding domain [48]. It is conceivable that
immobilization of ApoE to a plate can affect its con-
formation such that an ApoE conformer is created,
which is prone to stimulate TREM2 in the reporter
assay. However, ApoE interacting with TREM2 and
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displaying EC50 and Kd values in the same approximate
concentration range when immobilized (reporter assay)
and when in solution (binding and competition assays)
argues that such a potential effect is either very limited
or not relevant in our experiments.
Conclusions
In conclusion, we have proved the existence of a joint
signaling pathway between TREM2 and ApoE, the pro-
teins encoded by the two strongest genetic risk factors
for AD, and found that the human ApoE isoforms ε2,
ε3, and ε4 are all agonists to human and murine
TREM2, albeit with reduced potency to murine
TREM2. We have also determined binding affinities of
the human ApoE isoforms to human TREM2 and iden-
tified a potential TREM2-binding domain in the
receptor-binding region of human ApoE, which is con-
served among the human isoforms. Our findings lay
base for further studies on the pathophysiological rele-
vance of the ApoE-dependent TREM2 receptor signal-
ing. Within preclinical pharmacology, our work points
out the need to develop new transgenic models with
human TREM2 expression as to properly display the
interplay between ApoE and TREM2 on AD pheno-
types and to evaluate therapeutic strategies.
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